贝伐单抗联合化疗治疗晚期老年肺腺癌的临床疗效观察

Clinical Observation of Bevacizumab Combined with Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma

目的探讨贝伐单抗联合化疗治疗晚期老年肺腺癌的临床疗效。方法将120例晚期老年肺腺癌患者随机分为对照组与观察组,每组60例。对照组患者给予常规化疗,观察组患者在常规化疗的基础上给予贝伐单抗治疗。所有患者治疗结束后进行疗效,生存率,生活质量和不良反应的发生情况的评价。结果观察组与对照组有效率(CR+PR)分别是75.00%(45/60)与56.67%(34/60),差异具有统计学意义(χ~2=12.415,P=0.012)。观察组患者生活质量改善率为76.67%,显著高于对照组的55.00%,差异具有统计学意义(χ~2=6.432,P=0.040)。观察组与对照组患者的半年生存率分别为86.67%、81.67%,差异不具有统计学意义(χ~2=0.563,P=0.453);1年和2年生存率分别是61.67%、25.00%与43.33%、16.67%,2组1、2年生存率的比较,差异均具有统计学意义(χ~2=4.043,P=0.04;χ~2=9.571,P=0.021)。观察组患者治疗过程中不良反应的发生率与对照组相比,差异不具有统计学意义(χ~2=2.584,P=0.108)。结论贝伐单抗联合化疗治疗老年肺腺癌具有很好的疗效,能够提高患者的生存率,改善患者的生活质量,且不增加治疗所带来的不良反应,具有重要的临床价值。

Objective To observe the clinical effect of bevacizumab combined with chemotherapy in the treatment of advanced lung adenocarcinoma. Methods 120 patients with advanced lung adenocarcinoma were randomly divided into the control group and the observation group （ n =60）.The patients in the control group were given routine chemotherapy.The patients in the observation group were treated with bevacizumab on the basis of conventional chemotherapy.Efficacy,survival rate,quality of life and adverse events were evaluated. Results The effective rates （CR＋PR） of the observation group and the control group were 75.00%（45/60） and 56.67%（34/60） respectively,and the difference was statistically significant （χ^2=12.415, P =0.012）.The improvement rate of quality of life in the observation group was 76.67%,which was significantly higher than that of the control group 55.00%.The difference was statistically significant （χ^2=6.432, P =0.040）.The 6-month survival rates of the observation group and the control group were 86.67% and 81.67% respectively,and the difference was not statistically significant （χ^2=0.563, P =0.453）.The 1-year and 2-year survival rates were 61.67%,25.00%,and 43.33%,16.67%.The 1-year and 2-year survival rates of the 2 groups had statistically significant difference （χ^2=4.043, P =0.04;χ^2=9.571, P =0.021）.The incidence of adverse reactions during treatment in the observation group was not statistically significant compared with the control group （χ^2=12.485, P =0.036）. Conclusion Bevacizumab combined with chemotherapy in the treatment of elderly patients with lung adenocarcinoma has a good effect,can improve the survival of patients,improve the quality of life of patients,reduce the adverse reactions caused by treatment,has important clinical value.